Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT CVE:CZX TSE:FCR NYSE:SRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.23-1.1%$5.46$4.59▼$14.36$10.15M0.97,928 shs6,220 shsCZXCanada Zinc MetalsC$0.31+∞C$0.31C$0.22▼C$0.39C$51.69MN/A238,645 shs118,500 shsFCRFirst Capital RealtyC$0.00C$18.60▼C$22.79N/AN/A468,009 shs3.04 million shsSRZStellar Resources$0.00$0.00▼$0.00N/AN/AN/AN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-1.13%+0.97%+7.17%-9.67%-57.94%CZXCanada Zinc Metals0.00%0.00%0.00%0.00%0.00%FCRFirst Capital Realty0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.23-1.1%$5.46$4.59▼$14.36$10.15M0.97,928 shs6,220 shsCZXCanada Zinc MetalsC$0.31+∞C$0.31C$0.22▼C$0.39C$51.69MN/A238,645 shs118,500 shsFCRFirst Capital RealtyC$0.00C$18.60▼C$22.79N/AN/A468,009 shs3.04 million shsSRZStellar Resources$0.00$0.00▼$0.00N/AN/AN/AN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-1.13%+0.97%+7.17%-9.67%-57.94%CZXCanada Zinc Metals0.00%0.00%0.00%0.00%0.00%FCRFirst Capital Realty0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$47.50808.22% UpsideCZXCanada Zinc Metals 0.00N/AN/AN/AFCRFirst Capital Realty 0.00N/AN/AN/ASRZStellar Resources 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SRZ, BOLT, CZX, and FCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.31N/AN/A$29.89 per share0.17CZXCanada Zinc MetalsN/AN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AN/ASRZStellar ResourcesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$26.66N/AN/AN/AN/A-91.67%-53.19%11/11/2025 (Estimated)CZXCanada Zinc MetalsN/AN/A0.00∞N/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/A0.00N/AN/AN/AN/AN/AN/ASRZStellar ResourcesN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest SRZ, BOLT, CZX, and FCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BOLTBolt Biotherapeutics-$6.40-$4.46+$1.94-$4.46$0.82 million$1.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACZXCanada Zinc MetalsN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/ASRZStellar ResourcesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.563.113.11CZXCanada Zinc MetalsN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/ASRZStellar ResourcesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/ASRZStellar ResourcesN/AInsider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics6.10%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/ASRZStellar ResourcesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.80 millionNot OptionableCZXCanada Zinc Metals147,000166.73 millionN/ANot OptionableFCRFirst Capital RealtyN/AN/AN/ANot OptionableSRZStellar ResourcesN/AN/AN/ANot OptionableSRZ, BOLT, CZX, and FCR HeadlinesRecent News About These CompaniesThis tin junior could go inter-Stellar as it moves toward productionSeptember 16, 2025 | msn.comHere's Why We're Not Too Worried About Stellar Resources' (ASX:SRZ) Cash Burn SituationSeptember 7, 2025 | finance.yahoo.comStellar Resources Announces 40 Million Securities IssueAugust 26, 2025 | msn.comPleasing Signs As A Number Of Insiders Buy Stellar Resources StockJuly 29, 2025 | finance.yahoo.comCompanies Like Stellar Resources (ASX:SRZ) Are In A Position To Invest In GrowthMarch 31, 2025 | finance.yahoo.comStellar Resources Reaches AU$33m Market Cap Benefiting Insider Stock BuyingFebruary 18, 2025 | uk.finance.yahoo.comInsider Spends AU$103k Buying More Shares In Stellar ResourcesFebruary 18, 2025 | finance.yahoo.comStellar inks MOU with Aus Hualong in bid to synergise West TAS projectsDecember 3, 2024 | msn.comStellar Resources Hits Record Tin IntersectionNovember 18, 2024 | markets.businessinsider.comStellar acquires Elliott to expand product lineNovember 13, 2024 | tirebusiness.comTStellar Resources Gains Strong Shareholder SupportNovember 13, 2024 | markets.businessinsider.comStellar Industries Mobile Service Equipment Maker Elliott Machine WorksNovember 4, 2024 | rermag.comRStellar Announces Acquisition of Elliott Machine Works, Strengthening Market PositionNovember 3, 2024 | wasteadvantagemag.comWStellar Resources Director Acquires Additional SharesOctober 29, 2024 | markets.businessinsider.comStellar Resources Advances Heemskirk Tin Project Amid Mixed Tin PricesOctober 20, 2024 | markets.businessinsider.comStellar integration with Dune unlocks new analytics for cross-border paymentsOctober 17, 2024 | msn.comIndiana reports stellar clay rare earths grades in South Australia at MinosSeptember 26, 2024 | msn.comStellar Finds Niche With Fuel TrailersSeptember 19, 2024 | forconstructionpros.comFStellar Resources Ltd (SRZ)September 14, 2024 | investing.comBuy or Build Tech Solutions? Stellar Embraces BothSeptember 5, 2024 | mdm.comMMedia Sentiment Over TimeSRZ, BOLT, CZX, and FCR Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.23 -0.06 (-1.13%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$5.22 -0.01 (-0.19%) As of 09/19/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Canada Zinc Metals CVE:CZXC$0.31 +0.31 (+∞) As of 05/4/2018Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.First Capital Realty TSE:FCRStellar Resources NYSE:SRZSunrise Senior Living, Inc. (Sunrise) is a provider of senior living services in the United States, Canada and the United Kingdom. The Company offers a range of personalized senior living services, including independent living, assisted living, care for individuals with Alzheimer's and other forms of memory loss, nursing and rehabilitative care. At December 31, 2011, it operated 311 communities, including 269 communities in the United States, 15 communities in Canada and 27 communities in the United Kingdom, with a total unit capacity of approximately 30,733. In January 2013, Health Care REIT, Inc acquired Sunrise Senior Living, Inc. property portfolio. The Company also announced the sale of its management business to an entity formed by affiliates of Kohlberg Kravis Roberts & Co. L.P., affiliates of Beecken Petty O'Keefe & Company and Health Care REIT. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.